Intratumoral administration of DCs expressing CCL21 in mice induced anti-tumor immunity and markedly suppressed the growth of subcutaneous lung cancer, suggesting the benefit of CCL21 expression in DC-based cancer immunotherapy [20]. This evidence concerns the gene CCL21 and lung carcinoma.